UNSPSC 51314373: Loratadine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314373 Loratadine/pseudoephedrine is a Commodity code that sits at odds with the state and local contracting activity currently tagged under it. The recent opportunities posted against this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations specifically seek loratadine/pseudoephedrine or closely related antihistamine-decongestant combination products. The code shows little relevant recent activity aligned with its nominal scope; state and local governments do procure pharmaceuticals broadly — including prescription and OTC drugs — but current postings under this code do not target the specific drug combination the code names.

The mismatch between code and solicitation content suggests either a data-entry error in the posting systems or a tagging artifact. Issuers posting under this code span state health departments (Texas HHS), county health systems (Seminole County), and cooperative purchasing alliances serving multistate and multilocal jurisdictions (MMCAP, which includes Minnesota and Oregon). If your firm supplies antihistamine-decongestant combinations or generic pharmaceuticals broadly to state and local health systems, cooperative purchasing groups, or county health agencies, monitor this code for future activity; however, the current opportunity stream does not support pursue decisions based on these three postings alone.